Trial Profile
Clinical outcome of advanced EGFR-mutated NSCLC patients who developed acquired resistance to first generation EGFR inhibitors with positive plasma T790M treated with osimertinib in NSW, Australia.
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 11 Jul 2017
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CONTROL
- 11 Jul 2017 New trial record